Recent Stories
Like BIOCOM, California Life Sciences Association Extends Reach into L.A.
Local trade group California Life Sciences Association is expanding its footprint to Los Angeles, with a new L.A. office and partnerships with LA BioMed and Lab Launch.
Franz Och Leaves Human Longevity for Illumina's Grail
Franz Och, a former Google executive recruited in 2014 by J. Craig Venter’s Human Longevity, has left the firm for an opportunity with Illumina-backed Grail.
Fortis Therapeutics Raises $18 Million in Series A Round
San Diego life science upstart Fortis Therapeutics Inc. has closed an $18 million Series A round led by local venture capital firm Avalon Ventures.
Coworking Leader WeWork to Occupy Six Floors of Downtown Building
New York City-based WeWork announced Tuesday that it will open a 90,000-square-foot coworking facility in the heart of downtown San Diego.
FDA Grants Orphan Drug Designation to Fate Therapeutics Product
Fate Therapeutics Inc.'s lead investigative product, ProTmune, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration.
Imprimis Pharmaceuticals Cuts Staff, Closes Texas Facility
San Diego’s Imprimis Pharmaceuticals, a maker of compounded drugs, is reducing its expenses in hopes of reaching near-term profitability, the company announced Monday.
Allergan Acquires Akarna Therapeutics Inc. for $50 Million
Pharmaceutical giant Allergan Plc has acquired Akarna Therapeutics Inc. for $50 million.
Apricus Biosciences Plans to Raise $4.6M in Direct Offering of Common Stock
San Diego biopharma Apricus Biosciences Inc. is expected to raise $4.6 million in a direct offering of its common stock to institutional investors, the company said Sept. 23.
Allergan Buys Akarna Therapeutics for $50M
Pharmaceutical giant Allergan Plc has acquired Akarna Therapeutics Inc. for $50 million.
Apricus Biosciences Inc. Plans to Raise $4.6M in Direct Offering of Common Stock
San Diego biopharma Apricus Biosciences Inc. is expected to raise $4.6 million in a direct offering of its common stock to institutional investors, the company said Sept. 23.
